The benefits and dangers when genetic testing companies partner with orphan drug developers

September 27, 2017, Mary Ann Liebert, Inc
Credit: Mary Ann Liebert, Inc., publishers

Pharmaceutical companies developing Orphan Drugs are increasingly partnering with direct-to-consumer (DTC) genetic testing firms to identify individuals with rare diseases, in a trend that is raising concerns related to privacy, drug costs, and rising healthcare-related financial burden for consumers. An in-depth look at the enormous positive potential and concomitant dangers of these evolving corporate relationships and their impact on consumers and the healthcare system is published in Genetic Testing and Molecular Biomarkers.

In the article "Direct-to-Consumer Genetic Testing and Orphan Drug Development," coauthors Matthew Mason, James Levenson, MD, and John Quillin, PhD, Virginia Commonwealth University School of Medicine, Richmond, discuss the dynamics and key factors that affect these two sectors of the healthcare industry. The authors examine the science behind DTC and the industry's market growth, how drugs for rare diseases are regulated, the potential for innovation and applying genetic testing results to orphan drug development, and suggested oversight and safeguards needed to protect patients from threats to their privacy and possible price-gouging.

"This paper provides an excellent overview as well as a thoughtful perspective of the interactions between the commercial developers of and the patients and families that they aim to serve who are afflicted with ," says Genetic Testing and Molecular Biomarkers Editor-in-Chief Garth D. Ehrlich, PhD, FAAAS, Professor of Microbiology and Immunology, Executive Director, Center for Genomic Sciences and Center for Advanced Microbial Processing, Institute for Molecular Medicine and Infectious Disease, Drexel College of Medicine (Philadelphia, PA).

Explore further: Are biobank donor families worried about a confidentiality breach?

More information: Matthew Mason et al, Direct-to-Consumer Genetic Testing and Orphan Drug Development, Genetic Testing and Molecular Biomarkers (2017). DOI: 10.1089/gtmb.2017.0087

Related Stories

Are biobank donor families worried about a confidentiality breach?

April 5, 2017
A new study examines how well families that donate tissue to a biobank—or decide not to donate—understand the risk and implications of a potential confidentiality breach. The technology to acquire genome sequence data ...

A genetic variation may increase tuberculosis susceptibility

July 21, 2017
Researchers have shown that a single nucleotide change in a gene that affects production of hepcidin—a peptide involved in inflammation, immunity, and control of iron levels—is associated with greater susceptibility to ...

What's missing from current methods for genetic screening of sperm donors?

April 26, 2016
U.S. sperm banks perform genetic testing to screen for and disqualify carriers of a limited number of recessive disease mutations, but more comprehensive and affordable DNA-based screening methods are now available that can ...

Pharmaceutical companies are profiting from rare diseases: study

October 21, 2016
Incentives intended to stimulate the development of more treatments for rare diseases are being exploited to boost the profits of pharmaceutical companies, new research led by Bangor University shows.

New metabolomic screening method detects multiple inborn errors of metabolism in urine

November 3, 2016
Analysis of a single urine sample using a metabolomics-based screening approach can identify multiple different inborn errors of metabolism (IEMs), facilitating early disease detection and rapid initiation of treatment, as ...

Ethics complicate clinical interpretation and reporting of human genome sequence results

April 3, 2017
Medical use of a patient's genomic sequence information can improve diagnostic capabilities and enable personalized therapies, but technical and practical barriers to understanding the clinical implications of sequence data ...

Recommended for you

Early life experiences influence DNA in the adult brain

March 22, 2018
In the perennial question of nature versus nurture, a new study suggests an intriguing connection between the two. Salk Institute scientists report in the journal Science that the type of mothering a female mouse provides ...

Study reveals startlingly different tissue sensitivities to cancer-driving genes

March 22, 2018
New research led by Harvard Medical School and Brigham and Women's Hospital has unmasked hundreds of cancer-driving genes and revealed that different tissue types have shockingly variable sensitivities to those genes.

Does genome sequencing increase downstream costs?

March 22, 2018
As genome sequencing enters the clinic, fears have arisen about its potential to motivate follow-up testing and ongoing screening that could drastically increase health care spending. But few studies have quantified the downstream ...

First 'non-gene' mutations behind neurodevelopmental disorders discovered

March 21, 2018
In the largest study of its kind, genetic changes causing neurodevelopmental disorders have been discovered by scientists at the Wellcome Sanger Institute and their collaborators in the NHS Regional Genetics services. The ...

Two genes likely play key role in extreme nausea and vomiting during pregnancy

March 21, 2018
Most women experience some morning sickness during pregnancy, but about 2 percent of pregnant women experience a more severe form of nausea and vomiting.

Scientists identify genes that could inform novel therapies for EBV-related cancers

March 20, 2018
VCU Massey Cancer Center researchers have identified two genes that are responsible for governing the replication of the Epstein-Barr virus, an infection that drives the growth of several types of cancer. The discovery could ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.